FC
CRSP icon

FORA Capital’s CRISPR Therapeutics CRSP Stock Holding History

FORA Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,986
Closed -$242K – 920
2021
Q1 		$242K Sell
1,986
-13,560
-87% -$2.05M 0.08% 259
2020
Q4 		$2.38M Buy
15,546
+15,029
+2,907% +$1.78M 0.36% 56
2020
Q3 		$43K Sell
517
-10,198
-95% -$905K 0.03% 460
2020
Q2 		$787K Buy
+10,715
New +$627K 0.27% 92
2020
Q1 		– Sell
-2,598
Closed -$158K – 1080
2019
Q4 		$158K Buy
+2,598
New +$142K 0.02% 669

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

FORA Capital's CRSP Position: Q2 2021 in Review

FORA Capital sold out of CRISPR Therapeutics (CRSP) in Q2 2021, closing a stake of 1,986 shares — an estimated $242K sold.

FORA Capital first reported a position in CRSP in Q4 2019 and held it in 5 quarters. The position peaked at $2.38M in Q4 2020. 498 funds tracked by Wall St. Rank hold CRSP as of Q2 2021.

  • FORA Capital reported no remaining CRISPR Therapeutics position as of Q2 2021 after selling out during the quarter.
  • FORA Capital sold 1,986 CRISPR Therapeutics shares in Q2 2021, an estimated $242K.
  • FORA Capital first reported a position in CRISPR Therapeutics in Q4 2019 and held it in 5 quarters.
  • FORA Capital's CRISPR Therapeutics position peaked at $2.38M in Q4 2020.
  • 498 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2021.

Based on FORA Capital's 13F filing for Q2 2021, filed 16 Aug 2021.